Bio-Rad Laboratories (BIO-B) Accumulated Depreciation & Amortization (2009 - 2025)

Bio-Rad Laboratories (BIO-B) has 17 years of Accumulated Depreciation & Amortization data on file, last reported at $165.4 million in Q4 2025.

• Quarterly Accumulated Depreciation & Amortization rose 9.1% year-over-year to $165.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $165.4 million (up 9.1% YoY) and the FY2025 annual result came in at $165.4 million, up 9.1% from the prior year.
• Accumulated Depreciation & Amortization grew to $165.4 million in Q4 2025 per BIO-B's latest filing, from $151.6 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $1.1 billion in Q2 2023 and bottomed at $137.3 million in Q4 2022.
• The 5-year median for Accumulated Depreciation & Amortization is $971.9 million (2021), against an average of $700.2 million.
• Peak annual rise in Accumulated Depreciation & Amortization reached 2690.39% in 2021, while the deepest fall reached 0.72% in 2021.
• Tracing BIO-B's Accumulated Depreciation & Amortization over 5 years: stood at $137.6 million in 2021, then slipped by 0.22% to $137.3 million in 2022, then climbed by 6.26% to $145.9 million in 2023, then rose by 3.91% to $151.6 million in 2024, then rose by 9.1% to $165.4 million in 2025.
• Per Business Quant, the three latest BIO-B Accumulated Depreciation & Amortization figures stand at $165.4 million (Q4 2025), $151.6 million (Q4 2024), and $145.9 million (Q4 2023).

Peer Comparison